Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix announced its participation in the OIS Retina Innovation Summit and the ASRS Annual Meeting in Montréal, as well as the HC Wainwright Ophthalmology Virtual Conference later in July. Presentations at the ASRS meeting will feature Phase 3 SOL-1 trial results for OTX-TKI in neovascular age-related macular degeneration and analyses of real-world anti-VEGF treatment patterns. CEO Pravin U.
Key figures
- Drug Name
- AXPAXLI™ (also known as OTX-TKI)
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.